Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
You may also be interested in...
Deals Of The Week: Sunovion/Elevation, Janssen/Genmab, Alnylam/Monsanto
With Roche’s Pascal Soriot set to become AstraZeneca’s CEO on Oct. 1, Soriot’s success in merging Genentech into Roche may open up AZ’s business development strategy to large-scale M&A.
Janssen Boosts Multiple Myeloma R&D With Genmab Deal
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.
Genmab Ready For European Zalutumumab Filing Based On PFS Data, Searching For A Partner To Fund
Indications are a regulatory filing for the EGFR inhibitor in second-line head and neck cancer would be acceptable in Europe, though not in the U.S., CEO vande Winkel says.